IP Group subsidiary pleased with arthritis drug progress Intellectual property-based business IP Group noted on Wednesday morning that Istesso, formerly Modern Biosciences, has announced new data from a cohort of patients dosed as part of a phase 1 study of MBS2320, its investigational drug for the treatment of rheumatoid arthritis. Sourced through Scoop.it from: www.digitallook.com














